Congenital, Hereditary, and Neonatal Diseases and Abnormalities

The Medical Concierge Centrum Medyczne is advancing care for rare genetic skin disorders such as Recessive Dystrophic Epidermolysis Bullosa and Junctional Epidermolysis Bullosa, with trials aimed at testing innovative cell‑based therapies to improve healing and reduce disease burden.

  • Gene‑based therapeutic strategies for epidermolysis bullosa
  • Cellular regenerative approaches using MSCs
  • Pediatric safety and efficacy assessments

Collaboration with leading specialists in Warsaw supports the development of treatments that could transform outcomes for affected children.

Immune System Diseases

Research at the site focuses on chronic inflammatory conditions, notably Ulcerative Colitis, where investigators evaluate new biologic agents designed to induce durable remission and improve quality of life for patients.

  • Novel biologics targeting intestinal inflammation
  • Biomarker‑driven patient selection
  • Long‑term remission and safety monitoring

The trial framework integrates patient‑centered endpoints to better understand therapeutic impact in real‑world settings.

Neoplasms

At Medical Concierge Centrum Medyczne, oncology studies address advanced prostate cancer, specifically Metastatic Castration‑Resistant Prostate Cancer, by testing cutting‑edge antibody‑drug conjugates and combination immunotherapy to extend progression‑free survival.

  • Antibody‑drug conjugates for tumor targeting
  • Combination of immunotherapy with chemotherapy
  • Advanced imaging and progression‑free survival endpoints

The commercial organization behind the trials leverages a multidisciplinary team to accelerate access to promising cancer therapies.

Skin and Connective Tissue Diseases

The center’s dermatology program evaluates therapies for fragile skin conditions, building on work with epidermolysis bullosa to explore wound‑healing agents, matrix‑modulating treatments, and strategies that enhance patient comfort.

  • Topical and systemic agents for skin fragility
  • Matrix remodeling and scar reduction therapies
  • Quality‑of‑life and functional outcome measures

Participation in European research networks enables the site to contribute to broader advances in connective tissue disease management.